BACKGROUND: @entity1397 reduces the risk of non-cardioembolic @entity385 , but it is unclear whether it affects the severity and outcome of @entity64 . We aimed at evaluating the effect of prior treatment with @entity1397 on acute non-cardioembolic @entity385 severity and in-hospital outcome. METHODS: We prospectively studied 608 consecutive @entity1 (39.5% males, age 79.1    6.6 years) who were admitted with acute @entity385 . The severity of @entity64 was assessed at admission with the National Institutes of Health @entity64 Scale (NIHSS). Severe @entity64 was defined as NIHSS >= 21. The outcome was assessed using the dependency rates that prevailed at the time of discharge (i.e. modified Rankin scale between 2 and 5) and with in-hospital mortality. RESULTS: At admission, 397 @entity1 did not have @entity955 or @entity340 . Among these 397 @entity1 , 69 were receiving monotherapy with @entity1397 prior to @entity64 , 69 were receiving monotherapy with @entity117 and 236 @entity1 were not on any antiplatelet treatment. The prevalence of severe @entity64 was lower in @entity1 who were receiving @entity1397 than in @entity1 who were receiving @entity117 and @entity1 who were not on antiplatelets (1.4, 13.0 and 11.0%, respectively; p < 0.05). Independent predictors of severe @entity64 at admission were male gender (relative risk (RR) 0.31, 95% CI 0.12-0.78, p < 0.05) and treatment with @entity1397 prior to @entity64 compared with no antiplatelet treatment (RR 0.13, 95% CI 0.02-0.97, p < 0.05). Treatment with @entity117 prior to @entity64 did not predict severe @entity64 compared with no antiplatelet treatment (RR 1.24, 95% CI 0.51-2.98, p = NS). The rate of dependency at discharge did not differ between @entity1 who were receiving @entity1397 , @entity1 who were receiving @entity117 and those who were not on antiplatelets (57.9, 47.8 and 59.7%, respectively; p = NS). Independent predictors of dependency at discharge were age (RR 1.12, 95% CI 1.05-1.19, p < 0.001) and NIHSS at admission (RR 1.67, 95% CI 1.46-1.92, p < 0.001). In-hospital mortality rate also did not differ between @entity1 who were receiving @entity1397 , @entity1 who were receiving @entity117 and those who were not on antiplatelets (4.3, 4.3 and 5.0%, respectively; p = NS). The only independent predictor of in-hospital mortality was NIHSS at admission (RR 1.22, 95% CI 1.14-1.30, p < 0.001). CONCLUSIONS: Treatment with @entity1397 prior to acute non-cardioembolic @entity385 attenuates the severity of @entity64 at admission but does not appear to affect the functional outcome at discharge or the in-hospital mortality of these @entity1 .

Treatment with @entity1397 Prior to Acute @entity385 Attenuates XXXX Severity.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'Stroke'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['Clopidogrel', 'clopidogrel'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity340 :: ('MESH:D006349', 'Disease') :: ['heart valve disease'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity64 :: (MESH:D020521,Disease) :: ['Stroke']
